TY - JOUR
T1 - Epidemiology and Management of ST-Segment–Elevation Myocardial Infarction in Patients With COVID-19
T2 - A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry
AU - Bhatt, Ankeet S.
AU - Varshney, Anubodh S.
AU - Goodrich, Erica L.
AU - Gong, Jingyi
AU - Ginder, Curtis
AU - Senman, Balimkiz C.
AU - Johnson, Matthew
AU - Butler, Kayleigh
AU - Woolley, Ann E.
AU - de Lemos, James A.
AU - Morrow, David A.
AU - Bohula, Erin A.
N1 - Funding Information:
AHA’s suite of registries is funded by multiple industry sponsors. AHA’s COVID-19 Cardiovascular Disease Registry is partially supported by the Gordon and Betty Moore Foundation. The Get With The Guidelines programs are provided by the AHA.
Publisher Copyright:
© 2022 The Authors.
PY - 2022/5/3
Y1 - 2022/5/3
N2 - BACKGROUND: Early reports from the COVID-19 pandemic identified coronary thrombosis leading to ST-segment–elevation myocardial infarction (STEMI) as a complication of COVID-19 infection. However, the epidemiology of STEMI in patients with COVID-19 is not well characterized. We sought to determine the incidence, diagnostic and therapeutic approaches, and outcomes in STEMI patients hospitalized for COVID-19. METHODS AND RESULTS: Patients with data on presentation ECG and in-hospital myocardial infarction were identified from January 14, 2020 to November 30, 2020, from 105 sites participating in the American Heart Association COVID-19 Cardiovascular Disease Registry. Patient characteristics, resource use, and clinical outcomes were summarized and compared based on the presence or absence of STEMI. Among 15 621 COVID-19 hospitalizations, 54 (0.35%) patients experienced in-hospital STEMI. Among patients with STEMI, the majority (n=40, 74%) underwent transthoracic echocardiography, but only half (n=27, 50%) underwent coronary angiography. Half of all patients with COVID-19 and STEMI (n=27, 50%) did not undergo any form of primary reperfusion therapy. Rates of all-cause shock (47% versus 14%), cardiac arrest (22% versus 4.8%), new heart failure (17% versus 1.4%), and need for new renal replacement therapy (11% versus 4.3%) were multifold higher in patients with STEMI compared with those without STEMI (P<0.050 for all). Rates of in-hospital death were 41% in patients with STEMI, compared with 16% in those without STEMI (P<0.001). CONCLUSIONS: STEMI in hospitalized patients with COVID-19 is rare but associated with poor in-hospital outcomes. Rates of coronary angiography and primary reperfusion were low in this population of patients with STEMI and COVID-19. Adaptations of systems of care to ensure timely contemporary treatment for this population are needed.
AB - BACKGROUND: Early reports from the COVID-19 pandemic identified coronary thrombosis leading to ST-segment–elevation myocardial infarction (STEMI) as a complication of COVID-19 infection. However, the epidemiology of STEMI in patients with COVID-19 is not well characterized. We sought to determine the incidence, diagnostic and therapeutic approaches, and outcomes in STEMI patients hospitalized for COVID-19. METHODS AND RESULTS: Patients with data on presentation ECG and in-hospital myocardial infarction were identified from January 14, 2020 to November 30, 2020, from 105 sites participating in the American Heart Association COVID-19 Cardiovascular Disease Registry. Patient characteristics, resource use, and clinical outcomes were summarized and compared based on the presence or absence of STEMI. Among 15 621 COVID-19 hospitalizations, 54 (0.35%) patients experienced in-hospital STEMI. Among patients with STEMI, the majority (n=40, 74%) underwent transthoracic echocardiography, but only half (n=27, 50%) underwent coronary angiography. Half of all patients with COVID-19 and STEMI (n=27, 50%) did not undergo any form of primary reperfusion therapy. Rates of all-cause shock (47% versus 14%), cardiac arrest (22% versus 4.8%), new heart failure (17% versus 1.4%), and need for new renal replacement therapy (11% versus 4.3%) were multifold higher in patients with STEMI compared with those without STEMI (P<0.050 for all). Rates of in-hospital death were 41% in patients with STEMI, compared with 16% in those without STEMI (P<0.001). CONCLUSIONS: STEMI in hospitalized patients with COVID-19 is rare but associated with poor in-hospital outcomes. Rates of coronary angiography and primary reperfusion were low in this population of patients with STEMI and COVID-19. Adaptations of systems of care to ensure timely contemporary treatment for this population are needed.
KW - ST-segment–elevation myocardial infarction
KW - acute myocardial infarction
KW - coronavirus disease 2019
UR - http://www.scopus.com/inward/record.url?scp=85129781673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129781673&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.024451
DO - 10.1161/JAHA.121.024451
M3 - Article
C2 - 35470683
AN - SCOPUS:85129781673
SN - 2047-9980
VL - 11
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 9
M1 - e024451
ER -